1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Febrile Neutropenia Global Clinical Trials Review, H2, 2016

Febrile Neutropenia Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Febrile Neutropenia Global Clinical Trials Review, H2, 2016" provides an overview of Febrile Neutropenia clinical trials scenario. This report provides top line data relating to the clinical trials on Febrile Neutropenia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Febrile Neutropenia Global Clinical Trials Review, H2, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Febrile Neutropenia to Hematological Disorders Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Febrile Neutropenia to Hematological Disorders Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Febrile Neutropenia Therapeutics Clinical Trials 27
Prominent Drugs 29
Latest Clinical Trials News on Febrile Neutropenia 30
Jul 11, 2016: Coherus Announces Positive Topline Results For CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic And Pharmacodynamic Biosimilarity Study 30
Clinical Trial Profile Snapshots 31
Appendix 105
Abbreviations 105
Definitions 105
Research Methodology 106
Secondary Research 106
About GlobalData 107
Contact Us 107
Disclaimer 107
Source 108

List of Tables
Febrile Neutropenia Therapeutics, Global, Clinical Trials by Region, 2016* 6
Febrile Neutropenia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Febrile Neutropenia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Febrile Neutropenia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Febrile Neutropenia Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Febrile Neutropenia Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Febrile Neutropenia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
Febrile Neutropenia Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
Proportion of Febrile Neutropenia to Hematological Disorders Clinical Trials, G7 Countries (%), 2016* 14
Febrile Neutropenia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Febrile Neutropenia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Febrile Neutropenia to Hematological Disorders Clinical Trials, E7 Countries (%), 2016* 17
Febrile Neutropenia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Febrile Neutropenia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Febrile Neutropenia Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Febrile Neutropenia Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Febrile Neutropenia Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Febrile Neutropenia Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Febrile Neutropenia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Febrile Neutropenia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Febrile Neutropenia Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Febrile Neutropenia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Febrile Neutropenia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List of Figures
Febrile Neutropenia Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Febrile Neutropenia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Febrile Neutropenia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Febrile Neutropenia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Febrile Neutropenia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Febrile Neutropenia Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Febrile Neutropenia Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Febrile Neutropenia Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
Proportion of Febrile Neutropenia to Hematological Disorders Clinical Trials, G7 Countries (%), 2016* 14
Febrile Neutropenia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Febrile Neutropenia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Febrile Neutropenia to Hematological Disorders Clinical Trials, E7 Countries (%), 2016* 17
Febrile Neutropenia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Febrile Neutropenia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Febrile Neutropenia Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Febrile Neutropenia Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Febrile Neutropenia Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Febrile Neutropenia Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Febrile Neutropenia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Febrile Neutropenia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Febrile Neutropenia Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Febrile Neutropenia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Febrile Neutropenia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 106

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Asia-Pacific Animal Health Market - Forecast to 2021

Asia-Pacific Animal Health Market - Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The APAC animal health market is estimated to grow at a CAGR of 5.7% during the forecast period, to reach USD 20.25 billion by 2021 from USD 15.32 billion in 2016. Growth in this market can primarily be ...

Animal Antibiotics and Antimicrobials Market by Product, Mode of Delivery, Animal - Global Forecast to 2021

Animal Antibiotics and Antimicrobials Market by Product, Mode of Delivery, Animal - Global Forecast to 2021

  • $ 5650
  • Industry report
  • December 2016
  • by MarketsandMarkets

The global animal antibiotics and antimicrobials market is estimated to grow at a CAGR of 4.6% from 2016 to 2021, to reach USD 4.73 billion by 2021 from USD 3.77 billion in 2016. The growth of this market ...

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

  • $ 4995
  • Industry report
  • January 2017
  • by GBI Research

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance Summary The antibacterial drug market covers ...

Global Feed Antibiotics Market

December 2016 $ 4250

Acetic Acid Markets In China

January 2017 $ 4000

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in the UK

  • February 2017
    2 pages
  • Anti-Infective  

  • United Kingdom  

View report >

Anti-Infective Market in the US and Canada

  • February 2017
    6 pages
  • Anti-Infective  

  • Canada  

    United States  

View report >

Anti-Infective Market in the US

  • February 2017
    9 pages
  • Anti-Infective  

    Cell Therapy  

  • United States  

View report >

Related Market Segments :

Anti-Infective
Blood Disease

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.